First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab : final analysis of the randomized, phase III iLLUMINATE trial - Moreno, Carol (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ; Greil, Richard (Salzburg Cancer Research Institute-CCCIT (Àustria)) ; Demirkan, Fatih (Dokuz Eylul University (Turquía)) ; Tedeschi, Alessandra (Niguarda Ca Granda Hospital (Itàlia)) ; Anz, Bertrand (Tennessee Oncology (Estats Units)) ; Larratt, Loree (University of Alberta Hospital (Canadà)) ; Simkovic, Martin (University Hospital and Medical School Hradec (Txèquia)) ; Novak, Jan (Charles University (Txèquia)) ; Strugov, Vladimir (Almazov National Medical Research Centre (Rússia)) ; Gill, Devinder (Princess Alexandra Hospital) ; Gribben, John G. (Barts Cancer Institute) ; Kwei, Kevin (Pharmacyclics LLC) ; Dai, Sandra (Pharmacyclics LLC) ; Hsu, Emily (Pharmacyclics LLC) ; Dean, James P. (Pharmacyclics LLC) ; Flinn, Ian W. (Sarah Cannon Research Institute) ; Universitat Autònoma de Barcelona